Cancer Advances, Inc., is a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers and other cancers.  The company is focused on impacting human health and preventing the progression of these cancers by enhancing the adaptive immune system.   

The company’s lead compound, Polyclonal Antibody Stimulator (PAS) vaccine, is an immunomodulator potentially applicable in multiple cancer types including gastric, pancreatic, colorectal, and liver.  PAS already has been studied in multiple clinical trials, in over 1,500 subjects, and has demonstrated an excellent safety and tolerability profile.   

Cancer Advances exclusively owns PAS and is focused on developing PAS therapeutics for gastric, pancreatic and other cancers, and identifying synergy between treatment classes.  The company has cultivated an intellectual property portfolio that holds over 100 United States and worldwide patents related to PAS.  In addition, Cancer Advances has a trademark portfolio and strategy for pursuing other trademarks.   

Cancer Advances, Inc. is a wholly owned subsidiary of Cato BioVentures and is led by a seasoned management team with more than 100 years of combined industry experience. 

Meet Our Team

Executive Team

Lynda Sutton, President

Lynda Sutton, B.S. currently serves as the President and Chief Regulatory Officer for Cato Research, and President for Cancer Advances. Ms. Sutton has 25 years of experience in the drug development industry, specializing in the development of regulatory strategies for drugs and biologics. She has coordinated activities in various disciplines and has been involved in the development of new clinical entities, has overseen the preparation of FDA pre-meeting submissions, and has ensured that regulatory requirements necessary for the approval and launch of new products have been satisfied. She has served as the primary regulatory contact for more than 100 Biotech and pharmaceutical companies over the last 19 years. In addition, Ms. Sutton has cofounded several small biotechnology companies and serves as a member of the board of directors for several companies. She has expertise in the development of biological products, with emphasis on gene therapy and blood products, and in the development of oncological, anti-infective, and neuropharmacological products.

John Wingen, CFO

John Wingen has extensive operational and leadership experience, having served in executive leadership roles for over 25 years. For the last 10 years John has served in finance and operational roles in the drug development industry.  John has extensive experience both buying and selling companies and raising investment funds. 

Scientific Advisor

Jill P. Smith, M.D., Director of Clinical Gastroenterology and Oncology

Jill P. Smith, M.D., Director of Clinical Gastroenterology and Oncology for Cato Research, is a clinician scientist who is Board certified in Gastroenterology. She is a leading researcher in the field of Pancreatology and former President of the American Pancreas Association. She is the recipient of the European Basic Science research award for pancreas research. Dr. Smith served as the Director of Clinical and Translational Research in NIDDK at the National Institutes of Health until January 2014. As an independent researcher she has expertise in bench to bedside translational research, and FDA regulation. In October 2013 she served as the Moderator of the FDA GREAT-2 conference on conducting clinical trials in gastrointestinal disorders. Currently she is Full Professor at Georgetown University in Washington DC in the Department of Medicine, Division of Gastroenterology & Hepatology. 

Pioneering new medicines and redefining possibilities for cancer patients.

Cancer Advances
Westpark Corporate Center
4364 South Alston Avenue,
Suite 105 Durham, North Carolina
USA 27713

© 2024 Cancer Advances, Inc. All rights reserved.